Definitive Contract HHSN261201200085C

This is a federal contract award from the National Cancer Institute, a civilian agency, to Eutropics Pharmaceuticals, a small business contractor. The contract has a Ceiling Value of $199,860.00 and is a Definitive Contract with a Firm Fixed Price pricing type. The contract was awarded on September 30, 2010 with an Ultimate Completion Date of June 29, 2011. The place of performance is Boston, MA. This appears to be a standalone contract award and not part of a larger contract vehicle. The...

<p>This is a $299,356.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Entropia Biosciences Inc., a self-certified small disadvantaged business. The contract is for research and development in the biomedical field, specifically for a SBIR Program Phase I action. The contract has a set-aside designation for total small business. The award date was September 22, 2015, and the ultimate completion date is June 21, 2016.</p>

<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>

This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&amp;D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&amp;D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...

<p>This is a $149,499.00 firm fixed-price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency, to L-Nutra, Inc., a for-profit small business organization. The contract is for &quot;Medicinal Food for the Protection of Patients and Sensitization of Cancer Cells to Chemotherapy.&quot; It has a period of performance ending on April 7, 2011. The contract was awarded on September 30, 2010 and is set aside for small businesses.</p>

<p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>

This is a $1,498,266.01 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute, a civilian agency, to Eutropics Pharmaceuticals for the development of BH3 profiling as a companion diagnostic for Velcade treatment of multiple myeloma. The contract has a total small business set-aside designation and an ultimate completion date of March 2, 2016. This award appears to be part of the National Cancer Institute's broader efforts to support the development of diagnostics and...

This is a federal contract award from the National Cancer Institute, a civilian agency, to Zoneone Pharma Inc., a small business contractor. The contract is for &quot;OTHER FUNCTIONS - R &amp; D BIOMEDICAL (BASIC RESEARCH)&quot; with a ceiling value of $215,999.00. It is a definitive, firm fixed-price contract with a completion date of July 10, 2013. The place of performance is San Francisco, CA. As a small business set-aside award, this contract supports the National Cancer Institute's research...

<p>This is a $199,714.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency within the U.S. government, to String Therapeutics on September 20, 2012. The contract is for &quot;OTHER FUNCTIONS - R &amp; D BIOMEDICAL (BASIC RESEARCH)&quot; and has a total small business set-aside. The contract has an ultimate completion date of June 19, 2013.</p>

This is a $2,250,351.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a civilian agency, to Provid Pharmaceuticals Inc., a for-profit small business organization. The contract is for the MEDICINAL CHEMISTRY LEAD OPTIMIZATION, (PHASE II) SBIR TOPIC 198 research project under the Small Business Innovation Research (SBIR) program. The contract was awarded on August 31, 2005 and has an ultimate completion date of May 31, 2008. This contract is set aside for small...